LFSC · NASDAQ · ETF
F/m Emerald Life Sciences Innovation ETF (LFSC) Price, Holdings & Fees
F/m Emerald Life Sciences Innovation ETF (LFSC) closed at $307.86 on Oct 9, 2026, down 0.74% from the previous close of $310.14.
Share price, past year
1Y +21.18%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $307.86 |
| Sep 30, 2026 | $307.27 |
| Aug 31, 2026 | $295.68 |
| Jul 31, 2026 | $291.34 |
| Jun 30, 2026 | $298.22 |
| May 29, 2026 | $294.63 |
| Apr 30, 2026 | $290.08 |
| Mar 31, 2026 | $265.96 |
| Feb 27, 2026 | $292.93 |
| Jan 30, 2026 | $290.22 |
| Dec 31, 2025 | $276.51 |
| Nov 28, 2025 | $246.62 |
| Oct 31, 2025 | $242.10 |
Key statistics
- Expense ratio
- 0.54%
- as of Dec 31, 2025
- Net assets
- $105.1M
- as of May 31, 2026
- Holdings
- 40
- as of May 31, 2026
- 52-week range
- $240.36 – $313.63
F/m Emerald Life Sciences Innovation ETF's expense ratio is 0.54%: $54.00 a year on $10,000 invested.
Holdings
F/m Emerald Life Sciences Innovation ETF held 40 investments worth $105.06M as of May 31, 2026. Its largest holding was Travere Therapeutics Inc, at 7.67% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | Travere Therapeutics IncTVTX | 7.67% | $8.05M |
| 2 | Cogent Biosciences IncCOGT | 7.53% | $7.91M |
| 3 | LivaNova PLCLIVN | 7.11% | $7.47M |
| 4 | Spyre Therapeutics IncSYRE | 6.41% | $6.73M |
| 5 | Guardant Health IncGH | 5.52% | $5.80M |
| 6 | Mirum Pharmaceuticals IncMIRM | 4.92% | $5.17M |
| 7 | Corcept Therapeutics IncCORT | 4.79% | $5.03M |
| 8 | United Therapeutics CorpUTHR | 4.16% | $4.37M |
| 9 | VeraDermics IncMANE | 3.42% | $3.59M |
| 10 | Savara IncSVRA | 3.22% | $3.39M |
| 11 | Cytokinetics IncCYTK | 3.16% | $3.32M |
| 12 | Nektar TherapeuticsNKTR | 3.14% | $3.30M |
| 13 | Trevi Therapeutics IncTRVI | 3.12% | $3.27M |
| 14 | Dianthus Therapeutics IncDNTH | 3.09% | $3.24M |
| 15 | Axsome Therapeutics IncAXSM | 2.84% | $2.98M |
| 16 | Billiontoone IncBLLN | 2.73% | $2.87M |
| 17 | TransMedics Group IncTMDX | 2.68% | $2.82M |
| 18 | Viridian Therapeutics IncVRDN | 2.23% | $2.35M |
| 19 | ICU Medical IncICUI | 2.09% | $2.20M |
| 20 | Corvus Pharmaceuticals IncCRVS | 1.95% | $2.05M |
| 21 | Palvella Therapeutics IncPVLA | 1.95% | $2.04M |
| 22 | Ceribell IncCBLL | 1.55% | $1.63M |
| 23 | Globus Medical IncGMED | 1.27% | $1.33M |
| 24 | Xeris Biopharma Holdings IncXERS | 1.22% | $1.28M |
| 25 | Bridgebio Pharma IncBBIO | 1.17% | $1.23M |
Top 25 of 40 holdings, as of May 31, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 100.04% |
| Country | % of fund |
|---|---|
| United States | 91.98% |
| United Kingdom | 7.11% |
| Singapore | 0.95% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to May 31, 2026, F/m Emerald Life Sciences Innovation ETF's total return was +8.19%, as reported to the SEC.
| Month | Total return |
|---|---|
| May 31, 2026 | +3.64% |
| Apr 30, 2026 | +8.53% |
| Mar 31, 2026 | −3.81% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- F/m Emerald Life Sciences Innovation ETF
- Ticker
- LFSC
- Exchange
- NASDAQ
- Fund type
- ETF
- Trust
- RBB FUND, INC.
- SEC series ID
- S000088167
- SEC CIK
- 0000831114
- Fractional shares
- No
Recent SEC filings
- Jul 28, 2026
- 485BPOSProspectus updateAug 31, 2026
- 485BPOSProspectus updateAug 25, 2026
- Jul 2, 2026
- 485BPOSProspectus updateJul 2, 2026
- 485BPOSProspectus updateJun 9, 2026
- May 7, 2026
- 485BPOSProspectus updateFeb 10, 2026
Shareholder reports and prospectuses are filed by RBB FUND, INC., the trust behind F/m Emerald Life Sciences Innovation ETF, and cover all of its funds.
Frequently asked questions
What is LFSC's price?
F/m Emerald Life Sciences Innovation ETF (LFSC) closed at $307.86 on Oct 9, 2026, down 0.74% from the previous close of $310.14.
What is LFSC's expense ratio?
F/m Emerald Life Sciences Innovation ETF's expense ratio is 0.54%: $54.00 a year on $10,000 invested.
What does LFSC hold?
F/m Emerald Life Sciences Innovation ETF held 40 investments worth $105.06M as of May 31, 2026. Its largest holding was Travere Therapeutics Inc, at 7.67% of the fund. Its five largest holdings were Travere Therapeutics Inc, Cogent Biosciences Inc, LivaNova PLC, Spyre Therapeutics Inc, Guardant Health Inc.
How has LFSC performed?
Over the 3 months to May 31, 2026, F/m Emerald Life Sciences Innovation ETF's total return was +8.19%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of May 31, 2026 (filed Jul 28, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Dec 31, 2025. Prices are generated sample data for development. Data sources and disclosures